Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Morris Sherman

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Gastroenterology|March 11, 2021
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular CarcinomaAmit G Singal, Yujin Hoshida, David J Pinato, et al.
Hepatology (Baltimore, Md.)|December 10, 2008
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovirNancy Leung, Cheng-Yuan Peng, Hie-Won Hann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Hepatology Communications|March 4, 2022
A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinomaNan Lin, Yongping Lin, Jianfeng Xu, et al.
Journal of Hepatology|January 8, 2019
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patientsAdam Doyle, Andre Gorgen, Hala Muaddi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced CancerAlex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Journal of Clinical Gastroenterology|March 11, 2010
Hepatocellular carcinoma (HCC): a global perspectivePeter Ferenci, Michael Fried, Douglas Labrecque, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Gastroenterology|March 11, 2021
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular CarcinomaAmit G Singal, Yujin Hoshida, David J Pinato, et al.
Hepatology (Baltimore, Md.)|December 10, 2008
Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovirNancy Leung, Cheng-Yuan Peng, Hie-Won Hann, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 13, 2016
Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and CirrhosisRaoel Maan, Marjolein van Tilborg, Katja Deterding, et al.
Journal of Hepatology|June 26, 2012
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trialJordi Bruix, Jean-Luc Raoul, Morris Sherman, et al.
Hepatology (Baltimore, Md.)|August 3, 2013
Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR studyMichael W Fried, Maria Buti, Gregory J Dore, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 16, 2012
Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infectionSteven L Flamm, Eric Lawitz, Ira Jacobson, et al.
Hepatology Communications|March 4, 2022
A multi-analyte cell-free DNA-based blood test for early detection of hepatocellular carcinomaNan Lin, Yongping Lin, Jianfeng Xu, et al.
Journal of Hepatology|January 8, 2019
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patientsAdam Doyle, Andre Gorgen, Hala Muaddi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2015
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced CancerAlex A Adjei, Donald A Richards, Anthony El-Khoueiry, et al.
Journal of Clinical Gastroenterology|March 11, 2010
Hepatocellular carcinoma (HCC): a global perspectivePeter Ferenci, Michael Fried, Douglas Labrecque, et al.
Pageof 16